British Journal of Cancer · 2022 · 33 citations · 50 references
MedicineMolecular BiologyOncologyMetastasisMolecular ImagingMolecular OncologyCancer BiomarkersColorectal CancerMolecular Classification Of TumorsTumor ClassificationTumor ImagingTumor MarkersColorectal Cancer PrognosisColorectal Tumor ClassificationConsensus Molecular SubtypesFibroblast ActivationFibroblast Activation Protein ImagingRelapse-free SurvivalTherapy Resistance DetectionTumor Biomarker Discovery
Abstract Background In colorectal cancer (CRC), the consensus molecular subtype 4 (CMS4) is associated with therapy resistance and poor prognosis. Clinical diagnosis of CMS4 is hampered by locoregional and temporal variables influencing CMS classification. Diagnostic tools that comprehensively detect CMS4 are therefore urgently needed. Methods To identify targets for molecular CMS4 imaging, RNA sequencing data of 3232 primary CRC patients were explored. Heterogeneity of marker expression in relation to CMS4 status was assessed by analysing 3–5 tumour regions and 91.103 single-tumour cells (7 and 29 tumours, respectively). Candidate marker expression was validated in CMS4 peritoneal metastases (PM; n = 59). Molecular imaging was performed using the 68 Ga-DOTA-FAPI-46 PET tracer. Results Fibroblast activation protein (FAP) mRNA identified CMS4 with very high sensitivity and specificity (AUROC > 0.91), and was associated with significantly shorter relapse-free survival ( P = 0.0038). Heterogeneous expression of FAP among and within tumour lesions correlated with CMS4 heterogeneity (AUROC = 1.00). FAP expression was homogeneously high in PM, a near-homogeneous CMS4 entity. FAPI-PET identified focal and diffuse PM that were missed using conventional imaging. Extra-peritoneal metastases displayed extensive heterogeneity of tracer uptake. Conclusion FAP expression identifies CMS4 CRC. FAPI-PET may have value in the comprehensive detection of CMS4 tumours in CRC. This is especially relevant in patients with PM, for whom effective imaging tools are currently lacking.
50
Integrated analysis of multimodal single-cell data
Yuhan Hao, Stephanie Hao, Erica Andersen‐Nissen et al. · Cell · 2021 · 16K citations · Full text
QuPath: Open source software for digital pathology image analysis
Peter Bankhead, Maurice B. Loughrey, José A. Fernández et al. · Scientific Reports · 2017 · 8.7K citations · Full text
Medicine, Cancer Biology, Pathology +17
The consensus molecular subtypes of colorectal cancer
Justin Guinney, Rodrigo Dienstmann, Xin Wang et al. · Nature Medicine · 2015 · 5.3K citations · Full text
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
Thierry André, Kai‐Keen Shiu, Tae Won Kim et al. · New England Journal of Medicine · 2020 · 3K citations · Full text
Medicine, Oncology, Pharmacology +17